AAN stock was delisted from NYSE on
Oct 3, 2024. You can explore more stocks from
Consumer Cyclical sector on this page.
RVMD Revolution Medicines Inc
- Stocks
- Healthcare
- NASDAQ: RVMD
Price (delayed)
$41.91
Market cap
$7.81B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.01
Enterprise value
$7.6B
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities
Highlights
The company's equity rose by 20% YoY but it fell by 8% QoQ
The gross profit has dropped by 100% year-on-year
The revenue has dropped by 100% year-on-year
Key stats
What are the main financial stats of RVMD
Market
Valuations
Earnings
Shares outstanding
186.27M
Market cap
$7.81B
Enterprise value
$7.6B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.75
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$789.43M
Net income
-$697.51M
EBIT
-$698.26M
EBITDA
-$685.48M
Free cash flow
-$601.72M
Per share
Balance sheet
Liquidity
EPS
-$4.01
EPS diluted
-$4.01
Free cash flow per share
-$3.2
Book value per share
$11.18
Revenue per share
$0
TBVPS
$12.19
Total assets
$2.37B
Total liabilities
$287.2M
Debt
$134.34M
Equity
$2.08B
Working capital
$1.98B
Debt to equity
0.06
Current ratio
13.46
Quick ratio
13.28
Net debt/EBITDA
0.3
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-32.8%
Return on equity
-37.1%
Return on invested capital
-41.4%
Return on capital employed
-31.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RVMD stock price
How has the Revolution Medicines stock price performed over time
Intraday
11.29%
1 week
3.13%
1 month
34.63%
1 year
9.4%
YTD
-4.18%
QTD
18.52%
Financial performance
How have Revolution Medicines's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$789.43M
Net income
-$697.51M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% year-on-year
The revenue has dropped by 100% year-on-year
Revolution Medicines's net income has decreased by 44% YoY and by 16% from the previous quarter
RVMD's operating income is down by 43% year-on-year and by 14% since the previous quarter
Price vs fundamentals
How does RVMD's price correlate with its fundamentals
Growth
What is Revolution Medicines's growth rate over time
Valuation
What is Revolution Medicines stock price valuation
P/E
N/A
P/B
3.75
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 12% since the previous quarter and by 5% year-on-year
The company's equity rose by 20% YoY but it fell by 8% QoQ
The P/B is 7% higher than the 5-year quarterly average of 3.5
The revenue has dropped by 100% year-on-year
Efficiency
How efficient is Revolution Medicines business performance
RVMD's ROIC is up by 17% year-on-year but it is down by 10% since the previous quarter
Revolution Medicines's return on equity has decreased by 11% QoQ
RVMD's ROA is down by 10% QoQ and by 2.2% YoY
Dividends
What is RVMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RVMD.
Financial health
How did Revolution Medicines financials performed over time
Revolution Medicines's total liabilities has soared by 57% YoY but it has decreased by 2% from the previous quarter
Revolution Medicines's current ratio has decreased by 27% YoY and by 5% from the previous quarter
The debt is 94% less than the equity
The debt has soared by 53% YoY
The debt to equity has grown by 20% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.